Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy
Here, we report a patient with gastric adenosquamous carcinoma (ASC) with human epidermal growth factor receptor-2 (HER2) overexpression who was successfully treated with trastuzumab-based chemotherapy. The patient was a 66-year-old man preoperatively diagnosed with gastric adenocarcinoma with no ev...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2014-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/362088 |
| _version_ | 1818438170384007168 |
|---|---|
| author | Shigenori Kadowaki Yasushi Yatabe Sohei Nitta Yuichi Ito Kei Muro |
| author_facet | Shigenori Kadowaki Yasushi Yatabe Sohei Nitta Yuichi Ito Kei Muro |
| author_sort | Shigenori Kadowaki |
| collection | DOAJ |
| description | Here, we report a patient with gastric adenosquamous carcinoma (ASC) with human epidermal growth factor receptor-2 (HER2) overexpression who was successfully treated with trastuzumab-based chemotherapy. The patient was a 66-year-old man preoperatively diagnosed with gastric adenocarcinoma with no evidence of distant metastases. On histopathological examination, the curatively resected tumor was identified as ASC with mixed adenocarcinoma and squamous cell carcinoma components. Multiple liver metastases developed 2.5 months after surgery. Because immunohistochemical staining for HER2 was strong in both components, combination chemotherapy with capecitabine, cisplatin, and trastuzumab was initiated. A partial response was confirmed after 6 treatment cycles and PET and CT scans performed after 13 cycles revealed disease resolution with no uptake in the metastatic lesions. No evidence of disease progression has been observed 16 months after initial chemotherapy. This report suggests the potential utility of trastuzumab-based chemotherapy for HER2-positive gastric ASC. |
| first_indexed | 2024-12-14T17:36:19Z |
| format | Article |
| id | doaj.art-e50b250dce944c85ab29027235e5b6a6 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-14T17:36:19Z |
| publishDate | 2014-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-e50b250dce944c85ab29027235e5b6a62022-12-21T22:52:58ZengKarger PublishersCase Reports in Oncology1662-65752014-03-017121021610.1159/000362088362088Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based ChemotherapyShigenori KadowakiYasushi YatabeSohei NittaYuichi ItoKei MuroHere, we report a patient with gastric adenosquamous carcinoma (ASC) with human epidermal growth factor receptor-2 (HER2) overexpression who was successfully treated with trastuzumab-based chemotherapy. The patient was a 66-year-old man preoperatively diagnosed with gastric adenocarcinoma with no evidence of distant metastases. On histopathological examination, the curatively resected tumor was identified as ASC with mixed adenocarcinoma and squamous cell carcinoma components. Multiple liver metastases developed 2.5 months after surgery. Because immunohistochemical staining for HER2 was strong in both components, combination chemotherapy with capecitabine, cisplatin, and trastuzumab was initiated. A partial response was confirmed after 6 treatment cycles and PET and CT scans performed after 13 cycles revealed disease resolution with no uptake in the metastatic lesions. No evidence of disease progression has been observed 16 months after initial chemotherapy. This report suggests the potential utility of trastuzumab-based chemotherapy for HER2-positive gastric ASC.http://www.karger.com/Article/FullText/362088Adenosquamous carcinomaStomachHuman epidermal growth factor receptor-2Trastuzumab |
| spellingShingle | Shigenori Kadowaki Yasushi Yatabe Sohei Nitta Yuichi Ito Kei Muro Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy Case Reports in Oncology Adenosquamous carcinoma Stomach Human epidermal growth factor receptor-2 Trastuzumab |
| title | Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy |
| title_full | Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy |
| title_fullStr | Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy |
| title_full_unstemmed | Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy |
| title_short | Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy |
| title_sort | durable response of human epidermal growth factor receptor 2 positive gastric adenosquamous carcinoma to trastuzumab based chemotherapy |
| topic | Adenosquamous carcinoma Stomach Human epidermal growth factor receptor-2 Trastuzumab |
| url | http://www.karger.com/Article/FullText/362088 |
| work_keys_str_mv | AT shigenorikadowaki durableresponseofhumanepidermalgrowthfactorreceptor2positivegastricadenosquamouscarcinomatotrastuzumabbasedchemotherapy AT yasushiyatabe durableresponseofhumanepidermalgrowthfactorreceptor2positivegastricadenosquamouscarcinomatotrastuzumabbasedchemotherapy AT soheinitta durableresponseofhumanepidermalgrowthfactorreceptor2positivegastricadenosquamouscarcinomatotrastuzumabbasedchemotherapy AT yuichiito durableresponseofhumanepidermalgrowthfactorreceptor2positivegastricadenosquamouscarcinomatotrastuzumabbasedchemotherapy AT keimuro durableresponseofhumanepidermalgrowthfactorreceptor2positivegastricadenosquamouscarcinomatotrastuzumabbasedchemotherapy |